Filtering
- P-321 Ophthalmic Solution
- P-321 Ophthalmic Solution placebo
- P-CHOP
- P03277
- P1101
- P1101 (Ropeginterferon alfa-2b)
- P1101 + Ribavirin
- P144 cream
- P1446A-05
- P276-00
- P2Et (Caesalpinia spinosa extract)
- P2Y12 antagonist monotherapy
- P2Y12 inhibitor
- P38 Inhibitor (4)
- P53 gene therapy
- P7435
- PA
- PA-824
- PA101
- PA1010
- PA21
- PA21 (2.5 g tablet containing 500 mg iron)
- PA32540
- PAC-1
- PAC-14028
- PAC-14028 cream 0.1%
- PAC-14028 cream 0.3%
- PAC-14028 cream 1.0%
- PAC-14028 cream vehicle
- PACAP38
- PACLITAXEL
- PAH medication
- PAN-90806 Ophthalmic Solution
- PARIET 20 mg DR tabs
- PARP Inhibitor BGB-290
- PARP inhibitor
- PAZ-417
- PAZ320
- PAZOPANIB
- PB-201
- PB-201 matched placebo
- PB127 for Injectable Suspension
- PB127 for injectable suspension
- PB2452 Infusion
- PBCLN-003
- PBF-509
- PBF-677
- PBF-680
- PBF-999
- PBI-100 Topical Cream
- PBI-200
- PBI-200 Tablet
- PBI-4050
- PBI-4050/ Placebo
- PBI4050
- PBK-1801
- PBO
- PBT2
- PBTZ169
- PC14586
- PC786
- PC945
- PCA
- PCA Morphine
- PCD
- PCI-24781
- PCI-32765
- PCI-32765 (Ibrutinib)
- PCK3145
- PCO371
- PCS499
- PCSK9 Inhibitor [EPC]
- PCSK9 inhibitor
- PD 0200390
- PD 0332334
- PD 0332991
- PD 0360324
- PD P 506 A
- PD-0325901
- PD-0332334
- PD-0332991
- PD-1
- PD-1 Antibody
- PD-1 Inhibitor Tislelizumab maintenance therapy
- PD-1 Inhibitors
- PD-1 and ACE2 Knockout T Cells
- PD-1 antibody
- PD-1 blocking antibody
- PD-1 inhibitor
- PD-1 inhibitors
- PD-1 mAb
- PD-1 monoclonal antibody
- PD-1/PD-L1 inhibitor
- PD-1/PD-L1 inhibitors
- PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab
- PD-217,014
- PD-L1 inhibitor
- PD0332991
- PD1 antibody
- PD1/PDL1 inhibitor
- PDC-1421 Capsule
- PDC-APB
- PDE9i
- PDNO
- PDR001
- PDS 1.0
- PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
- PE0139 Injection
- PEG
- PEG 3350
- PEG 3350 plus electrolytes
- PEG 400
- PEG IFN alfa-2a
- PEG asparaginase
- PEG+lactulose
- PEG- IFNα2b
- PEG-ADA ERT
- PEG-Asc
- PEG-Asparaginase
- PEG-ELS
- PEG-ELS (Golytely)
- PEG-G-CSF
- PEG-IFN
- PEG-IFN alfa-2a
- PEG-IFNα
- PEG-IFNa 2a
- PEG-Interferon alfa 2a
- PEG-Intron
- PEG-L-asparaginase
- PEG-Tα1
- PEG-asparaginase
- PEG-filgrastim
- PEG-liposomal prednisolone sodium phosphate
- PEG-rhG-CSF
- PEG-somatropin
- PEG3350
- PEGASYS
- PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)
- PEGCETACOPLAN (APL-2)
- PEGPH20
- PEGylated Recombinant Human Hyaluronidase (PEGPH20)
- PEN-221
- PEP005
- PEP005 (ingenol mebutate) Gel
- PEP005 (ingenol mebutate) Gel, 0.05%
- PEP005 Gel
- PEP005 Topical Gel
- PEP02
- PEP503
- PER977
- PET
- PET Scan with PF-03654746
- PEX168
- PEX168(100µg)
- PEX168(200µg)
- PF
- PF - 00610355
- PF 03882845 and Placebo
- PF 05212389 or placebo
- PF-00217830
- PF-00232798
- PF-00299804
- PF-00337210
- PF-00345439
- PF-00446687
- PF-00489791
- PF-00547659 SC Injection
- PF-00547659 SC injection
- PF-00610355
- PF-00734200 20 mg QD
- PF-00868554
- PF-00868554 or Placebo
- PF-00885706
- PF-01367338
- PF-01913539 5 mg
- PF-02341066
- PF-02341066/PF-00299804
- PF-02545920
- PF-03049423
- PF-03084014
- PF-03446962
- PF-03463275
- PF-03526299
- PF-03654746
- PF-03654764
- PF-03715455
- PF-03716539
- PF-03882845
- PF-03882845 or Placebo
- PF-03893787
- PF-04136309
- PF-04171327
- PF-04171327 25 mg
- PF-04191834
- PF-04191834 placebo
- PF-04217329
- PF-04217329 - High Dose
- PF-04217329 - Low Dose
- PF-04217329 - Middle Dose
- PF-04217329 - Vehicle